CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins

Abstract excerpt

Acute myeloid leukemia (AML), the most common hematologic malignancy, generally has a poor prognosis. Despite initial favorable responses to the BCL2 inhibitor venetoclax (VEN), remission is transient, and AML is eventually fatal. Resistance to VEN is primarily due to the overexpression of anti-apoptotic proteins, including MCL-1, BCL2L1 (BCL-XL), and BCL2A1. Casein kinase II (CK2) is a serine-threonine kinase and...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Aged
• Antineoplastic Agents
• Chronic Lymphocytic Leukemia Research
• fms-Like Tyrosine Kinase 3
• Leukemia, Myeloid, Acute
• Mutation
• Protein Degradation and Inhibitors

Identifiers and source

Literature Corpus work

6a541551-c9b6-525e-927c-347e033b0a2e

DOI

10.64898/2025.12.24.696284